Treatment Options for??Multidrug-Resistant Acinetobacter Species
- 1 January 2008
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 68 (2) , 165-189
Abstract
Multidrug-resistant Acinetobacter spp. are emerging nosocomial pathogens and have become a leading cause of Gram-negative infections in many parts of the world. Acinetobacter spp. are commonly implicated in bloodstream infection, hospital-acquired pneumonia, and wound and other surgical-site infections. They are difficult to treat, thus often leading to adverse patient outcome. Group II carbapenems (imipenem/cilastatin and meropenem) are the agents of choice for the treatment of severe infections caused by Acinetobacter spp. isolates susceptible to this antimicrobial group, but infection with carbapenem-resistant strains is increasingly encountered. Therapy of such infections necessitates the use of old drugs (e.g. colistin), unusual drugs (e.g. sulbactam) or drugs with which there is presently little clinical experience (e.g. tigecycline). Case reports, case series and small comparative observational studies suggest that these regimens are efficacious and demonstrate lower-than-expected toxicity, but there is substantial variation between these reports. Combination antimicrobial therapy is often used to treat infections caused by such multidrug-resistant strains. This article summarizes the cumulative experience with and the evidence for treating infections caused by multidrug-resistant Acinetobacter spp. infections. Special emphasis is placed on the use of ‘non-traditional’ antimicrobial agents, various aspects of combination therapy, alternative routes of drug administration, and discrete entities such as ventilator-associated pneumonia and postsurgical meningitis.Keywords
This publication has 177 references indexed in Scilit:
- “All-in-one-plate” E-test and disk diffusion susceptibility co-testing for multiresistant Acinetobacter baumanniiEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteriaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecyclineEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002–2004Diagnostic Microbiology and Infectious Disease, 2005
- Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-testEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumanniiDiagnostic Microbiology and Infectious Disease, 2005
- In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)Diagnostic Microbiology and Infectious Disease, 2005
- Use of Intravenous Polymyxin B During Continuous Venovenous HemodialysisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Cerebrospinal Fluid Penetration and Pharmacokinetic/Pharmacodynamic Parameters of Intravenously Administered Colistin in a Case of Multidrug-Resistant Acinetobacter baumannii MeningitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- Cloning, Nucleotide Sequencing, and Analysis of the Gene Encoding an AmpC β-Lactamase in Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2000